Biography

Chris Yang is the Chief Scientific Officer and Co-Founder of AusperBio Therapeutics. He received his B.Sc. from Sichuan University, his M.S. from Memorial University of Newfoundland in Canada, and his Ph.D. in medicinal chemistry and molecular pharmacology from Purdue University.

Dr. Yang has extensive experience in drug discovery and development across oncology and infectious diseases. He began his career at SUGEN, Inc., where he spent four years working on kinase inhibitors and contributed to the discovery of SUTENT (sunitinib malate). He subsequently joined Gilead Sciences, where he spent fourteen years, first as a Senior Research Scientist and later as Director in the Drug Metabolism department.

At Gilead, Dr. Yang was a core member of the teams for multiple antiviral therapies. He contributed to the development of anti-HIV and anti-HBV drugs including Adefovir and Tenofovir Alafenamide (TAF), and played a central role in the discovery and development of the blockbuster anti-HCV drugs Harvoni, Epclusa, and Vosevi from discovery through clinical trials to regulatory approval in the United States and Europe. He was a recipient of the 2015 Heroes of Chemistry award from the American Chemical Society (ACS).

His research interests focus on drug discovery, drug metabolism and pharmacokinetics, and translating novel therapeutic concepts to approved medicines.